TY - JOUR
T1 - A retrospective observational study of glucocorticoid-induced diabetes mellitus with IgA nephropathy treated with tonsillectomy plus methylprednisolone pulse therapy
AU - Miyawaki, Yoshia
AU - Katsuyama, Takayuki
AU - Sada, Kenei
AU - Hiramatsu, Sumie
AU - Ohashi, Keiji
AU - Morishita, Michiko
AU - Katsuyama, Eri
AU - Watanabe, Haruki
AU - Takano-Narazaki, Mariko
AU - Toyota-Tatebe, Noriko
AU - Sunahori-Watanabe, Katsue
AU - Kawabata, Tomoko
AU - Inoue, Tatsuyuki
AU - Kinomura, Masaru
AU - Sugiyama, Hitoshi
AU - Wada, Jun
N1 - Publisher Copyright:
© 2017 Miyawaki et al.This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2017/5
Y1 - 2017/5
N2 - Aims To evaluate the incidence of GC-DM among patients with immunoglobulin A nephropathy (IgAN) and to confirm the risk factors for the development of GC-DM. Methods The medical records of patients with IgAN newly treated with the protocol of tonsillectomy combined with steroid pulse therapy were reviewed. The primary outcome was the development of GC-DM within the hospitalization period and during one year of follow-up. Results During hospitalization, 19 of the 95 patients developed GC-DM (20.0%), and the patients with GC-DM were significantly older and had a higher rate of family history of diabetes and higher HbA1c levels. The prevalence of hypertension was higher and the EGFR was numerically lower in patients with GC-DM than in those without. Older age (≥45 years) and a family history of diabetes emerged as independent risk factors for the development of GC-DM (odds ratio [OR], 6.3 and 95% confidence interval [CI], 1.6-27.6; OR, 4.4 and 95% CI, 1.2- 16.6, respectively). No patients were newly diagnosed with GC-DM during 1-year observation period at out-patient clinic. Conclusions Among the patients with IgAN, 20% developed GC-DM during the hospitalization period, confirming the family history of diabetes is clinically necessary before starting GC therapy.
AB - Aims To evaluate the incidence of GC-DM among patients with immunoglobulin A nephropathy (IgAN) and to confirm the risk factors for the development of GC-DM. Methods The medical records of patients with IgAN newly treated with the protocol of tonsillectomy combined with steroid pulse therapy were reviewed. The primary outcome was the development of GC-DM within the hospitalization period and during one year of follow-up. Results During hospitalization, 19 of the 95 patients developed GC-DM (20.0%), and the patients with GC-DM were significantly older and had a higher rate of family history of diabetes and higher HbA1c levels. The prevalence of hypertension was higher and the EGFR was numerically lower in patients with GC-DM than in those without. Older age (≥45 years) and a family history of diabetes emerged as independent risk factors for the development of GC-DM (odds ratio [OR], 6.3 and 95% confidence interval [CI], 1.6-27.6; OR, 4.4 and 95% CI, 1.2- 16.6, respectively). No patients were newly diagnosed with GC-DM during 1-year observation period at out-patient clinic. Conclusions Among the patients with IgAN, 20% developed GC-DM during the hospitalization period, confirming the family history of diabetes is clinically necessary before starting GC therapy.
UR - http://www.scopus.com/inward/record.url?scp=85020020626&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020020626&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0178018
DO - 10.1371/journal.pone.0178018
M3 - Article
C2 - 28562629
AN - SCOPUS:85020020626
SN - 1932-6203
VL - 12
JO - PLoS One
JF - PLoS One
IS - 5
M1 - e0178018
ER -